UNSPSC 51142018: Dehydrated alcohol injection

This classification denotes a fluid used to produce degeneration of nerve function (neurolysis) for control of chronic pain, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K9958V90M. European Medicines Agency schedules Alcohol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15995MIG. Dehydrated alcohol injection generally arises in the molecular formula C2H6O. The term 'dehydrated alcohol injection' is an FDA designation. SMILES: CCO.

UNSPSC 51142018 Dehydrated alcohol injection is a Commodity code that in recent state and local procurement shows little activity directly aligned with its nominal scope. The three most recent opportunities tagged to this code involve naloxone procurement, therapeutic pharmacy initiatives for prescription fulfillment, and generic multi-source pharmaceuticals and OTC products — none of which are dehydrated alcohol injections. Seminole County, Florida's IFB for naloxone and drug deactivation systems, the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products all represent health and wellness purchasing rather than injectable alcohol products. The issuing bodies span county health departments, state HHS commissions, and multi-state cooperative purchasing vehicles, but the mismatch between code assignment and actual scope suggests either miscoding in the source data or minimal legitimate procurement activity under this Commodity code within the state and local market.

Geographic activity in the recent pipeline includes Florida, Texas, and Minnesota, with multi-state reach through MMCAP. Seminole County's naloxone solicitation (IFB 60459723LAS, due July 26, 2023) called for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Texas HHS Commission's RFI (HHS0017013, April 3, 2026 deadline) sought vendor information on direct-to-manufacturer prescription programs, while MMCAP's RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The code's recent state and local activity does not reflect procurement of dehydrated alcohol injections; firms evaluating this code should verify whether genuine opportunities exist under the correct UNSPSC classification or whether activity has shifted to adjacent pharmaceutical and OTC procurement codes.